Bausch + Lomb Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bausch + Lomb Corporation on August 5, 2026. The report details significant changes to the Company's Board of Directors and the entry into a material definitive agreement with a departing director. The filing also references a press release issued on August 6, 2026, containing financial information for the quarter ended June 30, 2026.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. While the report references a press release containing financial information for the quarter ended June 30, 2026, the specific figures are not included in the body of this 8-K document.
Material Changes and Corporate Actions
- Board Resignations: Steven H. Collis, Karen L. Ling, Thomas W. Ross, Sr., and Andrew C. von Eschenbach, M.D. resigned from the Board effective August 5, 2026. The resignations were not due to any disagreement with the Company.
- New Appointments: Thomas J. Appio, Robert Chersi, Laurence Paul, M.D., and Barbara Trebbi were appointed to the Board effective August 5, 2026, to fill the vacancies. These appointments were made at the request of Bausch Health Companies Inc. (BHC), the Company's controlling shareholder.
- Compensation for Resigning Directors: The Company agreed to pay prorated cash compensation and accelerated the full vesting of outstanding 2026 annual restricted stock unit awards for the resigning directors.
- Consulting Agreement: The Company entered into a one-year consulting agreement with Thomas W. Ross, Sr. (the "Ross Agreement").
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on future outlook. The Ross Agreement includes a termination clause allowing either party to end the contract with 30 days' prior written notice, or the Company to terminate immediately for cause. The full text of the Ross Agreement is scheduled to be filed in the Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.
Investor Verification Checklist
- Verify the specific financial results for the quarter ended June 30, 2026, in the press release attached as Exhibit 99.1.
- Review the full text of the Ross Agreement in the upcoming Form 10-Q for the quarter ending September 30, 2026.
- Confirm the committee assignments and lead independent director status for the newly appointed directors in future filings.
- Assess the impact of the controlling shareholder (BHC) on the composition of the new Board.